🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the USA / NCT07511361
Recruiting Phase 2

Study of Efficacy and Safety of Tonlamarsen in Participants With a Recent Hospitalization and a Concurrent Episode of Acute Severe Hypertension

NCT07511361 · tracked via the Priya Life Science USA tracker
Sponsor
Kardigan, Inc.
Phase
Phase 2
Started
2026-06-23
Last updated
2026-09-02

Condition(s) studied

HypertensionAcute Severe HypertensionHypertensive EmergencyHypertensive Urgency

Investigational drug(s) / intervention(s)

TonlamarsenPlacebo

Tonlamarsen: Tonlamarsen will be administered subcutaneously (under the skin) every 4 weeks during the randomized part of the study

Placebo: Placebo will be administered subcutaneously (under the skin) every 4 weeks during the randomized part of the study

Study summary

The purpose of this study is to evaluate the blood pressure-lowering effect of tonlamarsen in adult participants who were recently hospitalized and concurrently experienced an episode of acute severe hypertension.

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
Key Inclusion Criteria: * Age 18 or older, body weight ≥ 50 kg with BMI ≤45.0 kg/m2 * Ready for discharge or recently discharged from the hospital to home (within the past 7 days) during which evaluation and/or treatment of acute severe hypertension (documented SBP ≥ 180 mmHg and/or DBP ≥ 110 mmHg) occurred, as measured by a healthcare provider (HCP) within the 24 hours preceding hospitalization or during the initial 24 hours of hospitalization * At Screening and Randomization visit, average resting office systolic blood pressure ≥ 145 mmHg * Presence of established cardiovascular or renal disease Key Exclusion Criteria: * Has known history of secondary hypertension * Any malignancy requiring treatment within 5 years (except for basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix that has been successfully treated) * Has abnormal thyroid function with clinical significance * Recent hospitalization for stroke, myocardial infarction or coronary revascularization within 30 days prior to screening * History of and/or obvious clinical signs or symptoms of cirrhosis or other significant liver disease * Alanine aminotransferase or aspartate aminotransferase \>2 x upper limit of normal * Most recent hospitalization was for non-cardiovascular or non-renal conditions

Primary outcome measure(s)

Trial sites (11)

FacilityCityRegionStatus
Western Nephrology and Metabolic Bone Disease, PC - Arvada Arvada Colorado Recruiting
Homestead Associates in Research Homestead Florida Recruiting
Progressive Medical Research Port Orange Florida Recruiting
Eagle Clinical Research Chicago Illinois Recruiting
Richmond University Medical Center (RUMC) Staten Island New York Recruiting
Research Innovations, LLC Beavercreek Ohio Recruiting
OnSite Clinical Solutions, LLC Fort Mill South Carolina Recruiting
Chattanooga Research & Medicine CHARM Chattanooga Tennessee Recruiting
Laguna Clinical Research Associates Laredo Texas Recruiting
Tapia Internal Medicine Clinic Paris Texas Recruiting
Baylor Scott and White Research Institute - Temple Temple Texas Recruiting

More Kardigan, Inc. trials in the USA

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07511361 on ClinicalTrials.gov ↗ ← All trials in the USA